Clinical Trial

Sacituzumab govitEcan in THYroid Cancers

Study acronym: SETHY
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC). The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-01-23; most recent amendment 2024-10-31.
Status change: Not Yet Recruiting → Recruiting 2024-09-23
Trial Details
NCT Number NCT06235216
Lead Sponsor Grupo Espanol de Tumores Neuroendocrinos
Collaborators: MFAR, Gilead Sciences
Conditions Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer
Enrollment 42 participants
Start Date 2024-09-13
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-11-01